CD274 and non-small cell lung carcinoma: Pooled results at 5 years of phase III trials Checkmate 017 (squamous NSCLC) and 057 (nonsquamous NSCLC) showed a larger benefit of nivolumab compared to docetaxel in patient with PD-L1-positive tumors (HR 0.61, IC 0.49–0.76) and a smaller benefit in patients with PD-L1-negative tumors (HR 0.76, IC 0.61–0.96), remaining statistically significant in both cases [33].